Research and Markets (http://www.researchandmarkets.com/research/b8d445/commercial_insight) has announced the addition of the "Commercial Insight: Psoriasis - Intellectual property drives growth" report to their offering.
The launch of new brands in both biologic and topical treatments in 2009 is shaking up the psoriasis market. Stelara (ustekinumab; Johnson & Johnson) is eagerly anticipated by dermatologists, and Datamonitor forecast strong uptake. However, the threat of biosimilars looms over all biologic therapies.
Scope
- Analysis of the current and future market dynamics in psoriasis across the US, France, Germany, Italy, Spain the UK and Japan
- Assessment of biologic, vitamin derivative, topical corticosteroid and immunomodulator classes
- Psoriasis-specific forecast data for indication scrutiny, but total brand data also included to put sales in context for brand and company
- Scenario forecasts for go/no-go on biosimilar legislation and the impact of possible additional cost containment measures
Highlights of this title
The biologics created $1.4 billion in psoriasis sales in 2008 across the seven major markets, contributing 55% of the $2.5 billion psoriasis market. However, the economic downturn resulted in a plateau in biologic sales in psoriasis in 2008. Following a double digit CAGR over the last 4 years, it will slow to 3.4% from 2008 to 2018.